Condition: Advanced Solid Tumors · Metastatic Solid Tumors · Non-small Cell Lung Cancer (NSCLC) · Sponsor: Revolution Medicines, Inc.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
This description comes directly from the study's public registry record.
Revolution Medicines Study Director · 1-844-2-REVMED · medinfo@revmed.com
Always discuss trial participation with your own doctor first.
| Eastern Connecticut Hematology and Oncology Associates | Norwich, Connecticut, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Dallas | Irving, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07397338